Last reviewed · How we verify
FLUCON®
FLUCON® is an azole antifungal that inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane.
FLUCON® is an azole antifungal that inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane. Used for Candidiasis (oropharyngeal, esophageal, and systemic), Cryptococcal meningitis, Other fungal infections (Aspergillus, Coccidioides, and other susceptible fungi).
At a glance
| Generic name | FLUCON® |
|---|---|
| Also known as | Fluorometholone |
| Sponsor | Military Hospital of Tunis |
| Drug class | Azole antifungal |
| Target | Fungal cytochrome P450 (lanosterol 14α-demethylase) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
By blocking the conversion of lanosterol to ergosterol, FLUCON® compromises the structural integrity and permeability of the fungal cell membrane, leading to cell death or growth inhibition. This mechanism is selective for fungal cells because they rely on ergosterol for membrane function, whereas mammalian cells use cholesterol instead.
Approved indications
- Candidiasis (oropharyngeal, esophageal, and systemic)
- Cryptococcal meningitis
- Other fungal infections (Aspergillus, Coccidioides, and other susceptible fungi)
Common side effects
- Nausea
- Headache
- Abdominal pain
- Diarrhea
- Hepatotoxicity
- Rash
Key clinical trials
- Dual-Polymer Hydroxypropyl Guar-and Hyaluronic Acid Lubricants in Rheumatoid Arthritis (PHASE4)
- Treatment of Corneal Infiltrates Secondary to Epidemic Keratoconjunctivitis (PHASE4)
- Multicenter, Randomized Study Evaluating the Value of Antitubercular Treatment During Recurent Anterior Uveitis (URBA) (PHASE3)
- Efficacy and Safety of Fluorometholone (FML) in Dry Eye Disease (Keratoconjunctivitis Sicca) (PHASE3)
- Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FLUCON® CI brief — competitive landscape report
- FLUCON® updates RSS · CI watch RSS
- Military Hospital of Tunis portfolio CI